SCHEMBL15207931

SCHEMBL15207931

N#Cc1cncc(-c2nccn3nc(Nc4ccc(OC(F)F)cc4)nc23)c1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SYK P43405 1/20 0.37
EIF2AK4 Q9P2K8 1/20 0.37
JAK2 O60674 6/20 0.36
JAK3 P52333 5/20 0.36
PTK2 Q05397 4/20 0.35
ROCK1 Q13464 2/20 0.34
GSK3A P49840 2/20 0.34
GSK3B P49841 2/20 0.34
MEN1 O00255 1/20 0.33
KMT2A Q03164 1/20 0.33
CYP11B2 P19099 1/20 0.33
TTK P33981 1/20 0.33
KCNH2 Q12809 1/20 0.33
SCN5A Q14524 1/20 0.33
SCN9A Q15858 1/20 0.33
ABL1 P00519 1/20 0.33
GRM5 P41594 1/20 0.33
CSNK2A1 P68400 1/20 0.32
AURKA O14965 1/20 0.32
ROCK2 O75116 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15207974 0.88 JAK2 (0.46) JAK2JAK3PTK2MEN1KMT2A
SCHEMBL15207419 0.88 ABL1 (0.45) SYKEIF2AK4JAK2JAK3KCNH2
SCHEMBL30790 0.87 JAK2 (0.39) SYKEIF2AK4JAK2JAK3PTK2
SCHEMBL15207273 0.85 AURKA (0.40) SYKEIF2AK4JAK2JAK3PTK2
SCHEMBL20904 0.85 ROCK1 (0.39) SYKEIF2AK4JAK2JAK3PTK2
SCHEMBL15207680 0.84 CHEK1 (0.36) SYKEIF2AK4JAK2JAK3PTK2
SCHEMBL19540 0.84 JAK2 (0.44) SYKEIF2AK4JAK2JAK3PTK2
SCHEMBL15207233 0.83 JAK2 (0.38) SYKEIF2AK4JAK2JAK3PTK2
SCHEMBL15207402 0.82 JAK2 (0.45) SYKEIF2AK4JAK2JAK3PTK2
SCHEMBL15208233 0.81 NUAK1 (0.39) SYKEIF2AK4JAK2JAK3PTK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2609098-B1 TRIAZOLOPYRAZINE DERIVATIVES MERCK PATENT GMBH (DE) 2016-07-13 EP disclosed
US-9023851-B2 Triazolopyrazine derivatives MERCK PATENT GMBH (DE) 2015-05-05 US disclosed
US-9023851-B2 Triazolopyrazine derivatives MERCK PATENT GMBH (DE) 2015-05-05 US disclosed
US-20130225568-A1 TRIAZOLOPYRAZINE DERIVATIVES MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) 2013-08-29 US disclosed
US-20130225568-A1 TRIAZOLOPYRAZINE DERIVATIVES MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) 2013-08-29 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130225568-A1 TRIAZOLOPYRAZINE DERIVATIVES SYK, IRAK1, ZAP70 SYK 1/4885EIF2AK4 1898/4885JAK2 5/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.